Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed and/or refractory multiple myeloma

Subcutaneous isatuximab in addition to pomalidomide and dexamethasone is in clinical development for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM). Multiple myeloma (MM) is a rare, incurable cancer of the plasma cells in the bone marrow. In MM, large amounts of abnormal plasma cells are produced which fill the bone marrow and interfere with the production of other cells, including red and white blood cells and platelets. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs (‘refractory’ MM). New treatments are necessary to prolong overall survival and improve quality of life of patients with this burdensome and incurable disease.